Mersana Therapeutics, Inc. (MRSN)

Market Cap	145.39M -42.0%
Revenue (ttm)	33.18M -4.8%
Net Income	-70.08M
EPS	-14.09
Shares Out	5.00M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	712,460
Open	28.90
Previous Close	29.04
Day's Range	28.78 - 30.39
52-Week Range	5.21 - 36.25
Beta	0.43
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2025

About MRSN

Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 clinical trial. Its preclinical products portfolio includes XMT-2068 and XMT-2175. It has strategic research and development collaborations with Janssen Biotech, Inc....

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 28, 2017
• Employees: 102
• Stock Exchange: NASDAQ
• Ticker Symbol: MRSN
• Website: https://www.mersana.com

Financial Performance

In 2024, Mersana Therapeutics's revenue was $40.50 million, an increase of 9.88% compared to the previous year's $36.86 million. Losses were -$69.19 million, -59.69% less than in 2023.

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Jan 1, 2000

Data Sources Report a data error